Loading
A phase 2 trial of CD19 t-haNK in non-Hodgkin lymphoma, run by ImmunityBio, Inc., now recruiting.
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma is a phase 2 interventional study registered as NCT07125872 by ImmunityBio, Inc., with 20 participants planned, started 2025-11-11 and due to reach its primary completion in 2027-05-25. Interventions recorded: CD19 t-haNK- IV Administration.
Shares ImmunityBio and the tag pipeline.
Shares ImmunityBio and the tag pipeline.
Shares ImmunityBio and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares ImmunityBio and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.